canyon landscape

The purpose of this study is to evaluate the safety and tolerability of BIIB100 in adults with ALS. There are three in-person visits, including an overnight inpatient hospital stay where the study medication is administered orally at one time point, and one final phone visit required for this study.

The trial may last about 7 weeks from the time of screening through the observation period.

Principal Investigators: Shafeeq Ladha, MD

Status
Open and enrolling subjects.
Location
Phoenix, Arizona
Primary Sponsor
Biogen